Novartis to use Google technology for eye care

by The Associated Press

Swiss drug developer Novartis will team with technology giant Google to develop a "smart" contact lens that could improve some eye conditions or help diabetics manage their disease.

Terms of the agreement between the companies were not detailed in a statement released Tuesday by Novartis.

The drugmaker said its Alcon eye care division will license Google technology and work with a team from Google to develop a lens that uses microchips and miniaturized electronics. Novartis is focused on developing a contact lens that can provide a continuous measurement of in by measuring tear fluid.

It also said the lens has the potential to help restore the eye's natural auto focus on near objects for patients with who can no longer read without glasses. Presbyopia is a condition where the eye loses its ability to focus.

"This is a key step for us to go beyond the confines of traditional disease management, starting with the eye," Novartis CEO Joseph Jimenez said in a statement.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Patent talk: Google sharpens contact lens vision

Apr 16, 2014

(Phys.org) —A report from Patent Bolt brings us one step closer to what Google may have in mind in developing smart contact lenses. According to the discussion Google is interested in the concept of contact ...

Eli Lilly to buy part of Novartis for $5.4 bn

Apr 22, 2014

US pharmaceutical giant Eli Lilly said Tuesday it has reached an agreement to acquire the animal health division of Novartis of Switzerland for $5.4 billion (3.9 billion euros).

Novartis tries to make UK hospitals use $1000 drug

Apr 24, 2012

(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments